Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training
United States: Food and Drug Administration
TRIUMPH
NCT00122330
October 2004
January 2006
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Scripps Cancer Center | La Jolla, California 92037 |
Stanford University Medical Center, Division of Hematology | Stanford, California 94305-5112 |
University of California at Los Angeles | Los Angeles, California 90095 |
Hartford Hospital, Cancer Clinical Research Office | Hartford, Connecticut 06102 |
Johns Hopkins University Medical Center | Baltimore, Maryland 21205 |
NYU Clinical Cancer Center | New York, New York 10016 |
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program | Philadelphia, Pennsylvania 19104 |
City of Hope National Medical Center, Div. of Hematology & Bone Marrow Transplant | Duarte, California 91010-3000 |
Cleveland Clinic, Dept. of Clinical Research | Weston, Florida 33331 |
Indiana University Cancer Pavilion, Div. of Hematology-Oncology, Hematological Malignancy Program/Immunology | Indianapolis, Indiana 46202 |
National Heart, Blood, and Lung Institute, National Institutes of Health | Bethesda, Maryland 20892 |
Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology | St. Louis, Missouri 63110-1093 |
Duke University Health System, Division of Cell Therapy, Heme Malignancies Program | Durham, North Carolina 27710 |